IDEXX LABORATORIES INC /DE — Director's Dealing 2016

Aug 9, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2016-08-08

Reporting Person: Williams Michael J PhD (Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-08	Common Stock	M	21432	$38.795	Acquired	63399	Direct
2016-08-08	Common Stock	S	21432	$108.9237	Disposed	41967	Direct
2016-08-08	Common Stock	M	42698	$38.49	Acquired	84665	Direct
2016-08-08	Common Stock	S	28128	$108.9604	Disposed	56537	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-08-08	Non-Qualified Stock Option (right-to-buy)	$38.795	M	21432	Disposed	2018-02-13	Common Stock (21432)	Direct
2016-08-08	Non-Qualified Stock Option (right-to-buy)	$38.49	M	42698	Disposed	2018-05-31	Common Stock (42698)	Direct

Footnotes

F1: Includes 76 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2016.

F2: Represents the weighted average sales price of the shares sold ranging from a low of $108.53 to a high of $109.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: Represents the weighted average sales price of the shares sold ranging from a low of $108.56 to a high of $109.33 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: Grant of option to buy 10,716 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on February 14, 2012, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F5: Grant of option to buy 21,439 shares of IDEXX Laboratories, Inc. common stock that became exercisable five annual installments beginning on June 1, 2012, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F6: Not applicable.